United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

'This will be one less arrow in the concern quiver.'

Pfizer-BioNTech want full FDA approval for their vaccine — will a ‘yes' improve vaccine hesitancy?

AstraZeneca

European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, raising new questions about potential side effects of the shot. What Happened: As part of a regular review of safety reports for the vaccine, the safety committee of EMA is analyzing data provided by AstraZeneca on cases of Guillain-Barre syndrome (GBS).

EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots

Pfizer's CEO said the waiver proposal "will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine.'

Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues

BioNTech and Pfizer announced a filing for full FDA approval of their COVID-19 vaccine.

Why BioNTech Stock Popped Today

Now that the U.S. is getting close to authorizing the first COVID-19 vaccine for younger teens, it will pave the way for immunizations to begin to reach a broader group of Americans at a time when the pace of vaccinations is slowing.

The U.S. prepares to begin giving COVID-19 shots to 12- to 15-year-olds as Pfizer's vaccine nears expanded authorization

Pfizer and BioNTech have submitted an application for full FDA approval of their COVID-19 vaccine.

What Would Full FDA Approval Mean for the Pfizer Vaccine?

PFE vs. NVO: Which Stock Is the Better Value Option?

PFE vs. NVO: Which Stock Should Value Investors Buy Now?

Pfizer began applying for full approval on Friday, a process that could take months.

Full FDA Approval Of Pfizer's Covid Shot Could Make Vaccine Mandates More Likely

Pfizer and BioNTech are asking the Food and Drug Administration for full regulatory approval of their jointly-produced COVID-19 vaccine. The move would allow the companies to produce and distribute the shots even after the coronavirus pandemic state of emergency is lifted. Reports that the companies were seeking full approval first came Friday from CNN and CNBC.

Pfizer and BioNTech are filing for full approval of their COVID-19 vaccine with the FDA

Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop. That followed patent questions that hurt shares.

Pfizer, BioNTech Seek Full FDA Approval For Covid Vaccine; Shares Pop

Apple

Aflac

Chevron

Essex Property Trust

ONEOK

Bank OZK

Prudential Financial

Phillips 66

Reinsurance Group of America

SPDR S&P 500 ETF Trust

Tesla

Texas Instruments

Cimarex Energy

Energy Select Sector SPDR Fund

The great reopening is just around the corner. Markets are flush with easy money, and pent-up savings will fuel an economic boom (and some inflation).

3 Hot Dividend Stocks For The Great Reopening

Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) have started the process to seek full approval from the U.S. Food and Drug Administration (FDA) for a COVID-19 vaccine. What Happened: The companies' vaccine was made accessible in the U.S. last December when the FDA issued an Emergency Use Authorization (EUA).

Pfizer And BioNTech Seek FDA's Full Approval For COVID-19 Vaccine

It's currently being administered in the US under an emergency use authorization.

Pfizer seeks full FDA approval of COVID-19 vaccine

Pfizer and BioNTech have begun submitting an application to the U.S. Food and Drug Administration for full approval of their Covid-19 vaccine.

Pfizer, BioNTech Ask FDA for Full Approval of Covid-19 Vaccine

The companies are the first COVID vaccine makers in the nation to apply for full approval, which would allow Pfizer to market the vaccine directly to consumers.

Pfizer-BioNTech seeks full FDA approval for COVID-19 vaccine

The Pfizer shot was the first Covid-19 vaccine to be approved under an emergency use authorization in December.

Pfizer Submits Application For Full FDA Approval Of Covid-19 Vaccine

Pfizer and BioNTech have started the regulatory process of seeking full approval for their Covid-19 vaccine for use in people 16 and older in the U.S.

Pfizer and BioNtech begin the process of seeking full FDA approval for their Covid vaccine

This strong performance can be attributed to a very high demand for Pfizer's Covid-19 vaccine, which garnered $3.5 billion in Q1 sales. While the company also revised its full-year 2021 EPS guidance upward to $3.55 to $3.65, we expect this figure to very conservative going by the expected rise in.

Should You Buy Pfizer For 25% Gains?

Pfizer Inc. and German partner BioNTech SE said Friday they have initiated rolling submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration for full approval of their COVID-19 vaccine in individuals 16 years of age and older. The vaccine was already granted emergency use authorization last December, a measure used by the FDA in emergency situations.

Pfizer and BioNTech start process of seeking full FDA approval of their COVID-19 vaccine

NEW YORK and MAINZ, GERMANY, May 7, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Data to support the BLA will be submitted by the Companies to the FDA on a rolling basis over the coming weeks, with a request for Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the agency.

Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine

It could determine the future success of the company's COVID-19 vaccine.

This May Be the Best News in Pfizer's Earnings Report

Mizuho Securities' Vamil Divan expresses concern about the company's post-coronavirus future.

If Pfizer's Vaccine Is a Winner, Why Did This Analyst Downgrade Its Stock?

Johnson & Johnson

Moderna

Novavax

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Covid vaccine makers' shares seesaw after Biden administration says it will back patent waivers

Vaccine stocks — including BioNTech and Moderna stocks — pared deep losses Thursday after German Chancellor Angela Merkel said that she opposed waiving Covid vaccine patent rights. The post Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents appeared first on Investor's Business Daily.

Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents

Pfizer stock briefly broke out in May after the company called for $26 billion in full-year coronavirus vaccine sales. Is PFE stock a buy right now?

News for Pfizer Stock (PFE)